AARON MANKIN: Open Payments
NPI 1295168276 · NASHVILLE, TN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$14,692 in 128 payments from 23 companies in 2025. Trend: 2023 $20,802 · 2024 $6,658 · 2025 $14,692
Speaker / faculty: $8,050Food & beverage: $3,039Travel & lodging: $2,341Consulting: $1,262
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 25 | $10,392 |
| AstraZeneca Pharmaceuticals LP | 5 | $1,382 |
| Ferring Pharmaceuticals Inc. | 4 | $649 |
| Sumitomo Pharma America, Inc. | 22 | $518 |
| Dendreon Pharmaceuticals LLC | 21 | $370 |
| PFIZER INC. | 15 | $301 |
| IMMUNITYBIO, INC. | 4 | $194 |
| ABBVIE INC. | 4 | $117 |
| Merck Sharp & Dohme LLC | 4 | $108 |
| Boston Scientific Corporation | 1 | $93 |
Products named: RYBREVANT, LYNPARZA, ADSTILADRIN, ERLEADA, GEMTESA, PROVENGE, Xtandi, ANKTIVA.
Industry payments across TN — which companies pay providers there.
